| Hans-Günter Meyer-Thompson | Amphetamine
MAPS Statement on FDA Complete Response Letter on MDMA-Assisted Therapy for PTSD New Drug Application
MAPS Statement on FDA Complete Response Letter on MDMA-Assisted Therapy for PTSD New Drug Application
San Jose, CA – The Multidisciplinary Association for Psychedelic Studies (MAPS) is evaluating the path forward for safe, legal access to MDMA-assisted therapy following the announcement from Lykos Therapeutics that the potential approval of midomafetamine (MDMA) capsules used in combination with therapy for PTSD will be delayed by FDA. (MAPS, USA, 09.08.2024)
https://maps.org/2024/08/09/maps-statement-on-fda-complete-response-letter-on-mdma-assisted-therapy-for-ptsd-new-drug-application/